background
aim
inflamm
play
key
role
atherosclerosi
complement
system
involv
atherogenesi
complement
receptor
play
role
facilit
clearanc
immun
complex
circul
limit
evid
suggest
may
involv
cardiovascular
diseas
investig
relationship
gene
polymorph
cardiovascular
risk
method
singl
nucleotid
polymorph
snp
within
region
n
chromosom
assess
particip
prosper
prospect
studi
pravastatin
elderli
risk
mean
age
year
random
pravastatin
mgday
placebo
follow
mean
year
logist
regress
adjust
gender
age
countri
use
pravastatin
use
assess
associ
snp
cardiovascular
diseas
result
snp
within
genom
region
gene
chromosom
extract
region
strong
ld
present
lead
occurr
two
haploblock
twelv
investig
snp
significantli
associ
risk
fatal
nonfat
myocardi
infarct
p
moreov
associ
snp
also
associ
level
serum
creactiv
protein
crp
global
pvalu
tail
strength
method
control
multipl
test
impli
null
hypothesi
associ
snp
reject
conclus
data
indic
genet
variat
within
gene
associ
inflamm
risk
incid
coronari
arteri
diseas
inflamm
play
key
role
develop
atherosclerosi
lipoprotein
migrat
subendotheli
space
induc
inflamm
foam
cell
format
atherosclerot
plaqu
develop
sever
inflammatori
marker
creactiv
protein
crp
leukocyt
count
associ
risk
cardiovascular
diseas
myocardi
infarct
level
crp
leukocyt
count
increas
main
stimul
hepat
synthesi
acut
phase
protein
crp
complement
system
involv
inflammatori
condit
lead
atherogenesi
termin
complement
complex
coloc
crp
human
atherosclerot
lesion
furthermor
elev
level
serum
complement
compon
associ
presenc
myocardi
infarct
predict
risk
futur
coronari
event
complement
receptor
found
membran
mani
cell
type
includ
erythrocyt
granulocyt
monocyt
macrophag
receptor
complement
protein
via
receptor
erythrocyt
carri
immun
complex
circul
spleen
liver
immun
complex
transfer
phagocyt
cell
recent
postul
erythrocyt
may
also
involv
clearanc
atherogen
lipoprotein
besid
role
clearanc
immun
complex
lipoprotein
also
inhibit
complement
activ
act
cofactor
factor
imedi
breakdown
larg
intraindividu
variat
number
molecul
per
erythrocyt
describ
valu
rang
less
molecul
per
cell
erythrocyt
loos
molecul
age
process
circul
acceler
sometim
revers
loss
describ
patient
sever
type
inflammatori
noninflammatori
diseas
sever
acut
respiratori
syndrom
tuberculosi
insulindepend
diabet
mellitu
system
lupu
erythematosu
addit
condit
sever
polymorph
gene
relat
erythrocyt
express
includ
c
g
snp
exon
g
snp
exon
hindiii
restrict
fragment
length
polymorph
rflp
c
intron
three
polymorph
strong
linkag
disequilibrium
ld
role
gene
cardiovascular
diseas
atherosclerosi
remain
unclear
goal
present
studi
investig
relationship
polymorph
cardiovascular
diseas
data
come
prospect
studi
pravastatin
elderli
risk
prosper
detail
descript
studi
publish
elsewher
short
elderli
subject
age
year
histori
vascular
diseas
increas
vascular
risk
enrol
scotland
ireland
netherland
primari
studi
endpoint
death
coronari
heart
diseas
nonfat
myocardi
infarct
mi
fatal
nonfat
stroke
secondari
endpoint
separ
coronari
cerebrovascular
compon
primari
endpoint
studi
protocol
approv
medic
ethic
committe
particip
institut
studi
subject
gave
written
inform
consent
studi
protocol
conform
ethic
guidelin
declar
helsinki
phase
project
whole
genom
wide
screen
perform
describ
detail
previous
gwa
studi
select
singl
nucleotid
polymorph
within
region
chromosom
n
plink
softwar
take
rel
stringent
r
threshold
use
ldlink
http
analysistoolsncinihgovldlink
observ
three
set
snp
r
matrix
snp
shown
supplementari
tabl
measur
perform
sampl
store
c
crp
measur
autom
particleenhanc
immunoturbidimetr
assay
roch
uk
method
interand
intraassay
coeffici
variat
determin
use
highsensit
enzymelink
immunosorb
assay
r
system
abingdon
uk
interand
intraassay
coeffici
variat
sensit
pgml
white
blood
cell
count
wbc
measur
fulli
autom
system
sysmex
toa
medic
electron
kobe
japan
allel
frequenc
estim
pairwis
ld
investig
snp
estim
plot
program
haploview
associ
snp
laboratori
measur
assess
linear
regress
adjust
sex
age
countri
logist
regress
use
associ
snp
cardiovascular
outcom
adjust
sex
age
countri
pravastatin
treatment
statist
analys
perform
plink
statist
softwar
http
pngumgh
harvardedupurcellplinkdownloadshtml
download
control
multipl
test
calcul
global
pvalu
use
tail
strength
method
short
tail
strength
measur
much
pvalu
set
differ
expect
uniform
distribut
null
hypothesi
sum
differ
singletest
statist
tail
strength
power
mani
small
effect
exist
data
sinc
snp
independ
empir
pvalu
comput
use
permut
snp
permut
block
keep
intact
relationship
covari
outcom
individu
test
base
coxmodel
coxph
permut
use
comput
parallel
use
packag
parallelizedynam
global
pvalu
comput
use
r
version
tabl
show
baselin
characterist
particip
prosper
studi
supplementari
tabl
show
characterist
subject
develop
fatal
nonfat
myocardi
infarct
versu
without
myocardi
infarct
mean
age
particip
year
approxim
femal
due
inclus
criteria
prosper
almost
particip
histori
vascular
diseas
mean
followup
studi
subject
year
rang
gwa
databas
includ
million
snp
extract
snp
within
genom
region
gene
chromosom
n
fig
show
gene
structur
locat
investig
snp
strong
ld
present
within
genom
region
lead
occurr
two
haploblock
shown
fig
snp
hardi
weinberg
equilibrium
p
followup
patient
develop
fatal
nonfat
mi
experienc
fatal
nonfat
stroke
die
cardiovascular
diseas
overal
mortal
twelv
investig
snp
significantli
associ
risk
fatal
nonfat
mi
snp
correspond
odd
ratio
mi
confid
interv
depict
fig
minor
allel
frequenc
snp
associ
decreas
risk
coronari
arteri
diseas
minor
allel
frequenc
snp
associ
increas
risk
seven
snp
associ
decreas
risk
mi
also
associ
lower
level
crp
henc
two
snp
associ
increas
risk
mi
show
associ
higher
crp
level
although
statist
signific
snp
associ
leukocyt
count
level
data
shown
global
pvalu
tail
strength
method
control
multipl
test
impli
null
hypothesi
associ
snp
reject
supplementari
fig
show
associ
investig
snp
vascular
allcaus
mortal
fatal
nonfat
stroke
line
result
risk
mi
snp
associ
decreas
risk
vascular
allcaus
mortal
snp
associ
increas
vascular
allcaus
mortal
snp
associ
decreas
vascular
mortal
allcaus
mortal
none
investig
snp
associ
risk
stroke
adjust
smoke
diabet
hypertens
averag
ldl
cholesterol
followup
histori
mi
histori
stroke
logtransform
crp
materi
chang
result
data
shown
investig
relationship
polymorph
cardiovascular
risk
prosper
prospect
random
trial
elderli
subject
receiv
pravastatin
placebo
mean
followup
year
snp
gene
associ
risk
fatal
nonfat
mi
addit
sever
snp
associ
decreas
risk
mi
also
associ
lower
level
crp
furthermor
mani
investig
snp
associ
risk
vascular
allcaus
mortal
date
two
previou
studi
investig
relationship
polymorph
cardiovascular
risk
buraczynska
et
al
found
gg
phenotyp
polymorph
correspond
decreas
express
preval
endstag
renal
diseas
patient
histori
cardiovascular
diseas
without
cardiovascular
diseas
contrast
boiocchi
et
al
describ
lower
preval
gg
variant
hypercholesterolem
patient
histori
coronari
arteri
diseas
healthi
control
howev
studi
total
number
patient
gg
variant
unfortun
polymorph
present
databas
gwa
previou
studi
assess
relationship
present
describ
snp
cardiovascular
diseas
howev
minor
allel
snp
associ
lower
erythrocyt
sediment
rate
lower
risk
mi
observ
carrier
minor
allel
lower
level
crp
line
previous
report
lower
inflamm
subject
sever
marker
inflamm
includ
crp
white
blood
cell
count
associ
increas
cardiovascular
risk
sever
snp
significantli
associ
cardiovascular
risk
present
studi
also
associ
level
crp
white
blood
cell
count
crp
synthes
liver
primarili
respons
crp
bind
relationship
snp
serum
creactiv
protein
level
betacoeffici
confid
interv
three
set
snp
separ
dot
line
p
phosphocholin
group
surfac
instanc
bacteria
activ
complement
system
induc
inflammatori
cascad
destroy
ligand
complex
crp
solubl
ligand
may
bind
erythrocyt
surfac
thu
clear
circul
direct
interact
crp
may
explain
observ
associ
snp
present
studi
found
evid
direct
effect
gene
polymorph
level
leukocyt
count
hypothes
mechan
behind
observ
relationship
polymorph
risk
coronari
arteri
diseas
involv
level
circul
erythrocyt
may
affect
cardiovascular
risk
sever
way
firstli
polymorph
lead
lower
express
cell
may
result
reduc
clearanc
immun
complex
circul
result
proinflammatori
therefor
proatherogen
situat
secondli
lower
express
may
proatherogen
due
less
bind
atherogen
lipoprotein
erythrocyt
previous
demonstr
vivo
circul
human
erythrocyt
abl
bind
atherogen
apolipoprotein
bcontain
lipoprotein
bind
lipoprotein
circul
blood
cell
associ
reduc
preval
atherosclerosi
possibl
bind
atherogen
particl
blood
cell
prevent
interact
endothelium
specul
erythrocyt
contribut
remov
lipoprotein
circul
vitro
ex
vivo
work
group
indic
like
candid
receptor
bind
lipoprotein
circul
blood
cell
limit
present
studi
quantifi
erythrocytebound
patient
know
whether
snp
lead
function
chang
protein
although
observ
relationship
crp
level
previous
report
relationship
erythrocyt
sediment
rate
suggest
function
anoth
limit
correct
multipl
test
common
bonferroni
correct
due
larg
number
snp
analyz
bonferroni
adjust
pvalu
would
howev
notic
check
haplotyp
structur
within
gene
two
major
haploblock
strong
ld
indic
investig
snp
independ
use
bonferroni
correct
would
conserv
instead
use
tail
strength
method
control
multipl
test
sinc
test
power
studi
strong
ld
depend
small
effect
size
sinc
found
signific
pvalu
test
well
consid
result
valid
falseposit
anoth
limit
data
obtain
singl
cohort
find
need
confirm
independ
cohort
addit
investig
group
subject
age
year
impact
gene
polymorph
influenc
inflamm
atherosclerosi
may
pronounc
group
elderli
individu
gene
polymorph
lead
prematur
death
age
may
underestim
true
effect
polymorph
furthermor
futur
studi
investig
function
snp
necessari
conclus
genet
variat
within
gene
associ
inflamm
risk
incid
coronari
arteri
diseas
data
strengthen
evid
role
complement
system
atherosclerosi
author
declar
anyth
disclos
regard
conflict
interest
respect
manuscript
prosper
studi
support
investig
initi
grant
obtain
bristolmy
squibb
prof
dr
j
w
jukema
establish
clinic
investig
netherland
heart
foundat
grant
support
genotyp
provid
seventh
framework
program
european
commiss
grant
netherland
genom
initi
netherland
consortium
healthi
age
grant
